Dubai: The 10th Gulf Cooperation Council (GCC) Regulatory Affairs Pharma Summit, hosted at Dubai's Movenpick Grand Al Bustan, brought together over 650 professionals, including government officials, industry leaders, and regulatory experts, to shape the future of pharmaceutical regulation.

According to Anadolu Agency, the summit on Feb. 17-18 featured discussions on key regulatory topics and was followed by the GCC Pharmacovigilance Training and GCC Medical Tender and Business Talk on Feb. 19-20, focusing on drug safety and procurement strategies. The event concluded on Feb. 21 with an exclusive eCTD Training, equipping professionals with the latest regulatory submission practices.

Ruqaya Al Bastaki from the Emirates Drug Establishment (EDE) delivered a keynote address at the summit's opening ceremony, emphasizing how the EDE is reshaping the UAE's regulatory landscape through expanded domains and innovative services to enhance healthcare safety. Mona Al Moussli, chairman of the GCC Regulatory Affairs Pharma Summit, stated that the summit serves as a crucial forum for discussing upcoming regulations and new guidelines shaping the pharmaceutical landscape.

Najiba Al Shezawy, co-chairman of the summit, highlighted the event's success, noting the impressive turnout and participation from top pharmaceutical companies. The event's diverse representation underscores its significance as a premier gathering for regulatory affairs professionals.

The summit also featured participation from key regulatory authorities and organizations across the region, including EDE, Emirates Health Services, Dubai Health Authority from the UAE; Saudi Food and Drug Authority from Saudi Arabia, and University Medical City from Oman, among others. The discussions provided valuable insights and networking opportunities, reinforcing the summit as a leading platform for transformation in the region.